drugset
Drugs / RMC-9805
last change May 2026 re-read 2 minutes ago

RMC-9805

also known as zoldonrasib

targets KRAS via inhibition

Developed for
non-small cell lung carcinoma · pancreatic ductal adenocarcinoma · colorectal cancer · metastatic neoplasm · pancreatic adenosquamous carcinoma
Investigated by
Revolution Medicines, Inc. · Summit Therapeutics · Tango Therapeutics, Inc.

Trials 6 · a red edge is where a trial was stopped

today NCT07621718 · Ph 3 NCT07397338 · Ph 1/2 NCT06922591 · Ph 1/2 NCT06445062 · Ph 1/2 NCT06162221 · Ph 1/2 NCT06040541 · Ph 1
202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06040541 Sep 2023 → Dec 2026 expected colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma Revolution Medicines, Inc. Recruiting No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT07397338 Jan 2026 → May 2029 expected colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma Revolution Medicines, Inc. Recruiting No outcome recorded
Phase 1/2 NCT06922591 May 2025 → Jun 2027 expected non-small cell lung carcinoma, pancreatic ductal adenocarcinoma Tango Therapeutics, Inc. Recruiting No outcome recorded
Phase 1/2 NCT06445062 May 2024 → May 2027 expected colorectal cancer, pancreatic ductal adenocarcinoma Revolution Medicines, Inc. Recruiting No outcome recorded
Phase 1/2 NCT06162221 Jan 2024 → Jun 2027 expected non-small cell lung carcinoma Revolution Medicines, Inc. Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT07621718 May 2026 → Dec 2028 expected pancreatic adenosquamous carcinoma, pancreatic ductal adenocarcinoma Revolution Medicines, Inc. Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as RMC-9805 “With or Without Zoldonrasib (RMC-9805) as First-line Treatment” NCT07621718 ↗
4

NCT06445062 ↗

NCT06922591 ↗

NCT06040541 ↗

NCT06162221 ↗
Known as zoldonrasib “This approach yielded orally bioavailable compounds with marked antitumor activity in multiple preclinical models of KRASG12D cancers, including the investigational agent...” PMID 40705880 ↗ Jul 2025
2

NCT07397338 ↗

NCT07621718 ↗
Action Inhibit “RMC-9805, a selective and orally bioavailable KRAS G12D(ON) inhibitor” NCT06040541 ↗
Route Oral “Oral Tablet” NCT06162221 ↗
Target KRAS “RMC-9805, a selective and orally bioavailable KRAS G12D(ON) inhibitor” NCT06040541 ↗